Home Physical Sciences Crystal structure of N′-[(1E)-(2,6-dichlorophenyl)-methylidene]adamantane-1-carbohydrazide, C18H20Cl2N2O
Article Open Access

Crystal structure of N′-[(1E)-(2,6-dichlorophenyl)-methylidene]adamantane-1-carbohydrazide, C18H20Cl2N2O

  • Haya I. Aljohar , Hazem A. Ghabbour , Mohammed S.M. Abdelbaky , Santiago Garcia-Granda and Ali A. El-Emam EMAIL logo
Published/Copyright: June 20, 2016

Abstract

C18H20Cl2N2O, orthorhombic, Pbca (No. 61), a = 8.1023(2) Å, b = 18.7063(4) Å, c = 22.5509(6) Å, V = 3417.91(14) Å3, Z = 8, Rgt(F) = 0.0496, wRref(F2) = 0.1535, T = 293(2).

CCDC no.:: 1450951

The asymmetric unit of the crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colorless prism Size 0.26 × 0.03 × 0.02 mm
Wavelength:Cu Kα radiation (1.5418)
μ:34.6 cm−1
Diffractometer, scan mode:Xcalibur, Onyx, Nova, ω
2θmax, completeness:139°, >99 %
N(hkl)measured, N(hkl)unique, Rint:14651, 3181, 0.070
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2771
N(param)refined:155
Programs:CrysAlisPRO [24], SHELXT [25], SHELX [26]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Cl10.05709(9)0.57373(4)0.43640(3)0.0529(2)
Cl20.45333(9)0.43699(4)0.27823(3)0.0511(2)
O10.3971(2)0.65850(10)0.18889(8)0.0411(4)
N10.1666(2)0.61834(11)0.23417(9)0.0354(5)
H10.06060.61670.23490.043*
N20.2591(2)0.57924(10)0.27392(8)0.0322(4)
C10.1386(3)0.70750(12)0.15542(10)0.0310(5)
C130.2619(3)0.50570(11)0.36015(10)0.0326(5)
C30.0248(3)0.66168(14)0.11591(11)0.0375(5)
H3A0.09090.63040.09110.045*
H3B−0.04590.63220.14050.045*
C110.2475(3)0.65977(12)0.19355(9)0.0304(5)
C120.1762(3)0.54631(12)0.31357(10)0.0331(5)
H120.06150.54800.31300.040*
C20.2492(3)0.75315(13)0.11537(11)0.0387(6)
H2A0.31580.72230.09040.046*
H2B0.32290.78180.13950.046*
C40.0332(3)0.75710(14)0.19440(11)0.0417(6)
H4A0.10430.78610.21930.050*
H4B−0.03750.72880.22000.050*
C170.4679(4)0.42118(15)0.39580(14)0.0475(7)
H170.55350.38950.38770.057*
C80.0304(4)0.75697(14)0.03766(12)0.0453(6)
H8A0.09630.72660.01210.054*
H8B−0.03680.78770.01280.054*
C140.2153(3)0.51428(12)0.41956(11)0.0381(5)
C90.1429(3)0.80229(13)0.07645(12)0.0425(6)
H90.21480.83140.05120.051*
C100.0391(4)0.85104(15)0.11556(13)0.0515(7)
H10A0.11060.88030.14010.062*
H10B−0.02710.88250.09100.062*
C7−0.0810(3)0.71083(15)0.07687(12)0.0451(6)
H7−0.15360.68180.05180.054*
C160.4185(4)0.43223(15)0.45313(14)0.0505(7)
H160.47130.40820.48380.061*
C5−0.0729(4)0.80563(16)0.15465(13)0.0518(7)
H5−0.14040.83700.17960.062*
C180.3903(3)0.45717(12)0.34994(12)0.0374(5)
C150.2910(4)0.47877(15)0.46575(12)0.0482(7)
H150.25680.48600.50470.058*
C6−0.1852(4)0.75930(17)0.11648(14)0.0549(8)
H6A−0.25510.78950.09210.066*
H6B−0.25570.73040.14170.066*

Source of material

2,6-Dichlorobenzaldehyde (1.75 g, 0.01 mol) was added to a solution of adamantane-1-carbohydrazide (1.94 g, 0.01 mol), in ethanol (15 mL), and the mixture was heated under reflux for 1 h. On cooling, the precipitated crystalline product was filtered, washed with cold ethanol, dried and crystallized from ethanol to yield 3.06 g (87%) of the title compound as colourless prismatic crystals. M.p. 529–531 K [23]. 1H NMR (DMSO-d6, 500.13 MHz): δ 1.65–1.69 (m, 6H, adamantane-H), 1.86–1.88 (m, 6H, adamantane-H), 2.0 (s, 3H, adamantane-H), 5.35 (s, 1H, NH), 7.15–7.25 (m, 3H, Ar-H), 7.95 (s, 1H, CH = N). 13C NMR (DMSO-d6, 125.76 MHz): δ 26.40, 33.51, 35.01, 39.99 (adamantane-C), 126.87, 130.05, 133.53, 134,95 (Ar-C), 143.69 (CH = N), 175.90 (C = O).

Experimental details

Carbon-bound H atoms were placed in calculated positions and were included in the refinement in the riding model approximation. The Uiso values of the nitrogen-bound H atom was set to 1.2Ueq(N).

Discussion

The broad and potent activity of adamantane-based derivatives has established as one of the biologically important scaffolds. Adamantane derivatives were reported to possess a wide spectrum of biological properties including antiviral [1], [2], [3], [4], [5], [6], [7], [8], anticancer [9], [10], antibacterial [11], [12], [13], [14], antifungal [15], antimalarial [16] and antidiabetic [17] activities. In addition, a number of hydrazide-hydrazone derivatives have been claimed to possess interesting biological activities [18], [19], [20], [21], [22]. In the present study, we report the X crystal structure of the title adamantane-1-carohydrazide-hydrazone as intermediate for the synthesis of surpassing potential chemotherapeutic agents [23].

The asymmetric unit cell of the title compound contains one molecule. All bond lengths and angles of the title molecule are in the expected ranges. The molecules are weakly connected in the crystal structure via four intermolecular hydrogen bonds, N1—H1⋯O1i, N1—H1⋯N2i, C4—H4B⋯O1i and C12—H12⋯O1i. The H⋯A distances are 2.31, 2.55, 2.50 and 2.46 Å, respectively and the angles are 125, 165, 154 and 125°, respectively. Symmetry codes: (i) x−1/2, y, −z+1/2.

Acknowledgements:

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the Research Group Project No. PRG-1436–23. We also acknowledge the financialsupport from Spanish Ministerio de Economía y Competitividad (MINECO-13-MAT2013–40950-R, FPI grant BES-2011–046948 to MSM-A).

References

1. Rabinovich, S.; Baldini, J. T.; Bannister, R.: Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 outbreak. Am. J. Med. Sci. 257 (1969) 328–335.10.1097/00000441-196905000-00005Search in Google Scholar

2. Davies, W. L.; Grunnert, R. R.; Haff, R. F.; McGahen, J. W.; Neumeyer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E.: Antiviral activity of 1-adamantamine (amantadine). Science 144 (1964) 862–863.10.1126/science.144.3620.862Search in Google Scholar

3. Hayden, F. G.; Gwaltney, J. M. I.; Van, C. R. L.; Adams, K. F.; Giordani, B.: Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob. Agents Chemother. 19 (1981) 226–233.10.1128/AAC.19.2.226Search in Google Scholar

4. Wendel, H. A.; Snyder, M. T.; Pell, S.: Trial of amantadine in epidemic influenza. Clin. Pharmacol. Therap. 7 (1966) 38–43.10.1002/cpt19667138Search in Google Scholar

5. Rosenthal, K. S.; Sokol, M. S.; Ingram, R. L.; Subramanian, R.; Fort, R. C.: Tromantadine: Inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22 (1982) 1031–1036.10.1128/AAC.22.6.1031Search in Google Scholar

6. Burstein, M. E.; Serbin, A. V.; Khakhulina, T. V.; Alymova, I. V.; Stotskaya, L. L.; Bogdan, O. P.; Manukchina, E. E.; Jdanov, V. V.; Sharova, N. K.: Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents. Antiviral Res. 41 (1999) 135–144.10.1016/S0166-3542(99)00006-6Search in Google Scholar

7. Balzarini, J.; Orzeszko, B.; Mauri, J. K.; Orzeszko, A.: Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones. Eur. J. Med. Chem. 42 (2007) 993–1003.10.1016/j.ejmech.2007.01.003Search in Google Scholar PubMed

8. El-Emam, A. A.; Al-Deeb, O. A.; Al-Omar, M. A.; Lehmann, J.: Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107–5113.10.1016/j.bmc.2004.07.033Search in Google Scholar PubMed

9. Sun, S. Y.; Yue, P.; Chen, X.; Hong, W. K.; Lotan, R.: The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. 62 (2002) 2430–2436.Search in Google Scholar

10. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lira, Á. R.: Inhibition of IκB kinase-β and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 51 (2008) 5431–5440.10.1021/jm800285fSearch in Google Scholar PubMed

11. Jia, L.; Tomaszewski, J. E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M.: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Brit. J. Pharmacol. 144 (2005) 80–87.10.1038/sj.bjp.0705984Search in Google Scholar PubMed PubMed Central

12. Al-Abdullah, E. S.; Asiri, H. H.; Lahsasni, S.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial, and anti-inflammatory activity, of novel S-substituted and N-substituted 5-(1-adamantyl)-1,2,4-triazole-3-thiols. Drug Des. Dev. Ther. 8 (2014) 505–518.10.2147/DDDT.S62465Search in Google Scholar

13. Kadi, A. A.; El-Brollosy, N. R.; Al-Deeb, O. A.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. Eur. J. Med. Chem. 42 (2007) 235–242.10.1016/j.ejmech.2006.10.003Search in Google Scholar

14. Kadi, A. A.; Al-Abdullah, E. S.; Shehata, I. A.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole Derivatives. Eur. J. Med. Chem. 45 (2010) 5006–5011.10.1016/j.ejmech.2010.08.007Search in Google Scholar

15. Omar, K.; Geronikaki, A.; Zoumpoulakis, P.; Camoutsis, C.; Soković, M.; Ćirić, A.; Glamoćlija, J.: Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg. Med. Chem. 18 (2010) 426–432.10.1016/j.bmc.2009.10.041Search in Google Scholar

16. Dong, Y.; Wittlin, S.; Sriraghavan, K.; Chollet, J.; Charman, S. A.; Charman, W. N.; Scheurer, C.; Urwyler, H.; Tomas, J. S.; Snyder, C.; Creek, D. J.; Morizzi, J.; Koltun, M.; Matile, H.; Wang, X.; Padmanilayam, M.; Tang, Y.; Dorn, A.; Brun, R.; Vennerstrom, J. L.: The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). J. Med. Chem. 53 (2010) 481–491.10.1021/jm901473sSearch in Google Scholar

17. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E.: 1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46 (2003) 2774–2789.10.1021/jm030091lSearch in Google Scholar

18. Manvar, A.; Bavishi, A.; Radadiya, A.; Patel, J.; Vora, V.; Dodia, N.; Rawal, K.; Shah, A.: Diversity oriented design of various hydrazides and their in vitro evaluation against Mycobacterium tuberculosis H37Rv strains. Bioorg. Med. Chem. Lett. 21 (2011) 4728–4731..10.1016/j.bmcl.2011.06.074Search in Google Scholar

19. Maccari, R.; Ottanà, R.; Vigorita, M. G.: In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: Part 14. Bioorg. Med. Chem. Lett. 15 (2005) 2509–2513..10.1016/j.bmcl.2005.03.065Search in Google Scholar

20. Kumar, P.; Narasimhan, B.; Yogeeswari, P.; Sriram, D.: Synthesis and antitubercular activities of substituted benzoic acid N′-(substituted benzylidene/furan-2-ylmethylene)-N-(pyridine-3-carbonyl)-hydrazides. Eur. J. Med. Chem. 45 (2010) 6085–6089.10.1016/j.ejmech.2010.08.030Search in Google Scholar

21. Khan, K. M.; Rasheed, M.; Ullah, Z.; Hayat, S.; Kaukab, F.; Choudhary, M. I.; Atta ur-Rahman, Perveen, S.: Synthesis and in vitro leishmanicidal activity of some hydrazides and their analogues. Bioorg. Med. Chem. 11 (2003) 1381–1387.10.1016/S0968-0896(02)00611-9Search in Google Scholar

22. Hadjipavlou-Litina, D.; Samadi, A.; Unzeta, M.; Marco-Contelles, J.: Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives. Eur. J. Med. Chem. 63 (2013) 670–674.10.1016/j.ejmech.2013.03.014Search in Google Scholar PubMed

23. Hassan, G. S.; El-Emam, A. A.; Gad, L. M.; Barghash, A. E. M.: Synthesis, antimicrobial and antiviral testing of some new 1-adamantyl analogues. Saudi Pharm. J. 18 (2010) 123–128.10.1016/j.jsps.2010.05.004Search in Google Scholar PubMed PubMed Central

24. Agilent (2014) CrysAlisPRO. Agilent Technologies UK Ltd, Yarnton, England..Search in Google Scholar

25. Sheldrick, G. M.: SHELXT-Integrated space-group and crystal-structure determination. Acta Crystallogr. C71 (2015) 3–8..10.1107/S2053273314026370Search in Google Scholar PubMed PubMed Central

26. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–120.10.1107/S0108767307043930Search in Google Scholar PubMed

Received: 2016-1-31
Accepted: 2016-6-5
Published Online: 2016-6-20
Published in Print: 2016-12-1

©2016 Haya I. Aljohar et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of the catena-poly-[bis(μ2-1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl-κN)-1,4-dihydroquinoline-3-carboxylato-κ2O,O′)nickel(II)] 5.5 hydrate, C32H44N6NiO11F2
  3. Crystal structure of catena-poly-[(μ2-2-(2-((2,6-dimethylphenyl)amino)phenyl)acetato-κ2O:O′)(μ2-2-(2-((2,6-dimethylphenyl)amino)phenyl)acetate-κ3O,O′:O′)cadmium(II)], C28H20N2Cl4O4Cd
  4. Crystal structure of catena-poly[dichlorido-(μ2-4-(pyridin-4-yl)-isophthalate-κ2O, O′)cadmium(II)] monohydrate, C13H11NO5Cl2Cd
  5. Crystal structure of poly-{[μ2-(E)-1,4-di(1H-imidazol-1-yl)but-2-ene-κ2N:N′][μ2-cyclohexane-1,4-dicarboxylato-κ4O,O′:O′′,O′′′]nickel(II)}, C18H22N4NiO4
  6. Crystal structure of aqua (5,5′-dicarboxy-(1,1′-biphenyl)-2,3′-dicarboxylato-κO) bis(1,10-phenanthroline-κ2N,N′)cadmium monohydrate, C40H28CdN4O10
  7. Crystal structure of 5-methoxy-N′-[(3Z)-5-chloro-1-(4-fluorobenzyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-1H-indole-2-carbohydrazide-DMSO (1/1), C25H18ClFN4O3 · C2H6OS
  8. Crystal structure of 5-methoxy-N′-[(3Z)-1-benzyl-5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-1H-indole-2-carbohydrazide-DMSO (1/1), C27H25FN4O4S
  9. Crystal structure of poly-[bis{μ2-N-(4-(1H-imidazol-1-yl)phenyl)-4-(1H-imidazol-1-yl)-N-phenylaniline-κ2N:N′)}-(μ2-naphthalene-2,6-dicarboxylato)-(μ4-naphthalene-2,6-dicarboxylato)dicadmium(II)], C36H25N5O4Cd
  10. Crystal structure of 1-(adamantan-1-yl)-3-(4-bromophenyl)thiourea, C17H21BrN2S
  11. Crystal structure of N′-[(1E)-(2,6-dichlorophenyl)-methylidene]adamantane-1-carbohydrazide, C18H20Cl2N2O
  12. Crystal structure of dichlorido{bis(2-hydroxyethyl)-5′-([2,2′:6′,2′′-terpyridin]-4′-yl)-[1,1′:3′,1′′-terphenyl]-4,4′′-dicarboxylate-κ3N,N′,N′′}zinc(II), C39H31Cl2N3O6Zn
  13. Crystal structure of 4,4′-(1,3,5,7-tetraoxo-3a,4,4a,5,7,7a,8,8a-octahydro-4,8-ethenopyrrolo [3,4-f]isoindole-2,6(1H,3H)-diyl)dibenzoic acid, C26H18N2O8
  14. Crystal structure of (E)-1-(4-(((E)-3,5-dichloro-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-ethyl oxime, C17H16Cl2N2O2
  15. The crystal structure of diaqua-(N-(2-hydroxy-5-nitrobenzyl)iminodiacetato-κ4-N,O,O′,O′′)chromium(III) based on synchrotron data, C11H13CrN2O9
  16. Crystal structure of ethyl 5-amino-3-(methylthio)-1-(1-phenyl-5-(thiophen-2-yl)-1H-pyrazole-3-carbonyl)-1H-pyrazole-4-carboxylate, C21H19N5O3S2
  17. Crystal structure of (E)-1-(4-(((E)-3,5-dibromo-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-methyl oxime, C17H16Br2N2O2
  18. Crystal structure of dibromido μ-oxalato-κ2O,O′:κ2O′′,O′′′−η6-p-cymenediosmium(II), C22H28Br2O4Os2
  19. Crystal structure of 2-(bromomethyl)-4-(4-chlorophenyl)-1-tosylpyrrolidine, C18H19BrClNO2S2
  20. Crystal structure of 5-(3-fluorobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; C13H11FN2O3
  21. Crystal structure of diethylammonium 1,3-dimethyl-2,4,6-trioxohexahydropyrimidin-5-ide, C10H19N3O3
  22. Crystal structure of 1,1-dimethyl-3-(2-phenylethyl)urea, C11H16N2O
  23. Crystal structure of 2-(4-methoxyphenyl)-1,3-thiazolo[4,5-b]pyridine, C13H10N2OS
  24. Crystal structure of 3-tert-butyl-7-azadioxindole, C11H14N2O2
  25. Crystal structure of 1-ferrocenyl-6-bromopyrene, C26H17BrFe
  26. Crystal structure of 3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide, C16H13BrFN3S
  27. Crystal structure of 2-amino-4-(3,5-ditrifluoromethylphenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo[b]pyran, C20H16F6N2O2
  28. The crystal structure of 2-amino-4-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13N3O4
  29. Crystal structure of 2-amino-4-(2, 4-dichlorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12Cl2N2O2
  30. Crystal structure of bis(μ2-chlorido)-bis(di-p-tolylhydroxyphosphine-κP)-bis(di-p-tolylphosphite-κP)dipalladium(II), C56H58Cl2O4P4Pd2
  31. Crystal structure of diaqua-bis(2-methyl-1H-imidazole-4,5-dicarboxylato-κ2-O,N)cadmium(II) tetrahydrate, C12H22CdN4O14
  32. Crystal structure of aqua-(5-nitrosalicylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)copper(II), C19H13CuN3O6
  33. Crystal structure of bis(4-(2-phenylpropan-2-yl)phenyl)amine, C30H31N
  34. Crystal structure of 2-amino-4-(3,5-difluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C18H16F2N2O2
  35. Crystal structure of 2-amino-4-(3,4,5-trifluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H11F3N2O2
  36. Crystal structure of an isomeric bis[(η5:η1-6,6-di-p-tolylpentafulvene)(η5-pentamethylcyclopentadienyl)titanium(III)]-μ2,η1:η1-dinitrogen complex, C60H66N2Ti2
  37. Crystal structure of 3,4-dinitropyrazole, C3H2N4O4
  38. Crystal structure of (4-vinylpyridine-κN)triphenyl tin(IV) chloride, C25H22ClNSn
  39. Crystal structure of tert-butyl 2-phenylethylcarbamate, C13H19NO2
  40. Crystal structure of (Z)-4-((E)-(4-chlorobenzyli-dene)hydrazono)-1-p-tolylpyrrolidine-3-carbonitrile, C19H17ClN4
  41. Crystal structure of bis(biphenyl-2,2′-dicarboxylato-κ2O:O′)-bis(1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxylato-κ2O,O′)dizinc(II)2.5 hydrate, C62H57N6Zn2O16.5F2
  42. Crystal structure of dichloridobis{μ2-2,2′-((1E,1′E)-(ethane-1,2-diylbis(azanylylidene))bis(methanylylidene))bis(4-chlorophenolato)-κ5O,N,N′,O′:O′}diiron(III), C32H24Cl6Fe2N4O4
  43. Crystal structure of 4-((4,4-dimethyl-2, 6-dioxocyclohexylidine)methylamino)-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide, C20H23N3O5S
  44. Crystal structure of poly-[aqua-μ2-aqua-μ2-(4,4′-oxybis(benzoato)-κ4O,O′:O′′,O′′′)cadmium(II)], C14H12O7Cd
  45. Crystal structure of aqua(μ2-biphenyl-2,2′-dicarboxylato-κ3O,O′:O′′)-(μ2-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxylato-κ2O,O′)cadmium(II) 1.5 hydrate, C62H60N6Cd2O19F2
  46. Crystal structure of dimethanolo-bis[μ-(2-(2-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)phenoxy)benzoato)-κ5O,O′,N:N′,N′′]dicopper(II) — methanol (1/2), C46H48Cu2N8O12
  47. Crystal structure of poly-[tetraaqua-bis(μ4-2,5-dibenzoyl-1,4-benzenedicarboxylato-κ4O1:O2:O3:O4)-μ2-2,5-dibenzoyl-1,4-benzenedicarboxylato-k4O5,O6: O5′,O6′-didysprosium(III)] tetrahydrate C33H26O13Dy
  48. Crystal structure of hexaaqua-bis(3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl) propionato-κ3O,O′:O′)-bis(3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)propionato-κO)-bis(3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)propionato-κ2O,O′)dineodymium(III) octahydrate, C60H76N18O32Nd2
  49. Crystal structure of poly-[triaqua-(μ3-3,4,5,6-tetrafluoro-1,2-phthalato-κ4O:O′:O′′,O′′′) (2,3,4,5-tetrafluoro-benzoato-κ2O,O′) praseodymium(III)], C15H7F8O9Pr
  50. The crystal structure of dichlorido (1,3-dimesityl-1H-3λ4-imidazol-2-yl)(isoquinoline-κN)palladium(IV) – ethylacetate (1/1), C34H39Cl2N3O2Pd
  51. Crystal structure of dichlorido(1,3-bis(2,6-dimethyl-phenyl)-1H-3λ4-imidazol-2-yl)(isoquinolinyl)palladium(IV), C28H27Cl2N3Pd
  52. Crystal structure of 5-(4-(1H-tetrazol-5-yl)phenyl)-1H-imidazol-3-ium 7-carboxy-1,3-dioxo-1H,3H-benzo[de]isochromene-6-carboxylate monohydrate 4,5-anhydride, C24H16N6O8
  53. Crystal structure of poly-[diaqua-bis(μ2-2-((1H-1,2,4-triazol-5-yl)thio)acetato-κ2N:O) cadmium(II)], C8H8CdN6O6S2
  54. Crystal Structure of (E)-3-(4-methoxyphenyl)-1-(2,3,4-tris(benzyloxy)-6-hydroxyphenyl)prop-2-en-1-one, C37H32O6
  55. Structure and photochromism of 1-(1,2-dimethylindol-3-yl)-2-[2-methyl-5-(3-fluorophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C26H18F7NS
  56. Crystal structure of two-dimensional coordination polymer poly-[μ2-azido-aqua-(μ2-pyrazine-2-carboxylato-κ3O,N:N′)nickel(II)], C5H5N5O3Ni
  57. Crystal structure of 2-amino-5-oxo-4-(3,5-bis(trifluoromethyl)phenyl)-4H,5H-pyrano [3,2-c]chromene-3-carbonitrile, C21H10F6N2O3
  58. Crystal structure of 4-(5-((2-methylbenzyl)thio)-4-phenyl-4H-1,2,4-triazol-3-yl)pyridine, C21H18N4S
  59. Crystal structure of 5-(2-chloro-5-nitrophenyl)-3-(4-chlorophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carbothioamide, C18H16Cl2N4O2S
  60. Crystal structure of 4-(benzofuran-2-yl)-2-(3-(4-fluorophenyl)-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)thiazole, C28H20FN3OS
  61. Crystal structure of bis(dicyanamido-κ1N)-tetrakis[1-benzyl-1H-1,2,4-triazole-κ1N]cobalt(II), CoC40H36N18
  62. Crystal structure of 1-benzyl-6-hydroxy-1,4,5,6-tetrahydropyridine-3-carbonitrile, C13H14N2O
  63. Crystal structure of 2-amino-7-methyl-4-(3,4-difluoro-phenyl)-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H10F2N2O3
  64. The crystal structure of 4-[(benzo[1,3]dioxol-5-ylmethylene)-amino]-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one, C19H17N3O3
  65. Crystal structure of 1,4-dihydro-1-phenylchromeno[4,3-c]pyrazole, C16H12N2O
  66. Crystal structure of N-(5-((3,5-dimethylisoxazol-4-yl)sulfonyl)quinolin-8-yl)benzamide, C21H17N3O4S
  67. Crystal structure of 3-amino-9-methoxy-1-phenyl-1H-benzo[f]chromene-2-carbonitrile, C21H16N2O2
  68. Crystal structure of 1,2-bis(4-methoxyphenyl)-2-((3-(trifluoromethyl)phenyl)amino)ethan-1-one, C23H20F3NO3
  69. Crystal structure of 2-amino-4-(2,4-dinitrophenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carbonitrile – ethanol (1:1), C21H16N4O8
  70. Crystal structure of catena-poly-[(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-ium-1-yl)-1,4-dihydroquinoline-3-carboxylate-κ2O,O′)-(μ2-4,4′-sulfonyldibenzoato-κ4O,O′:O′′,O′′′)zinc(II)] hemihydrate, C31H27ZnFN3O9.5S
  71. Crystal structure of 2-(2-bromophenyl)-5-methyl-1,3-dioxane-5-carboxylic acid, C12H13BrO4
  72. Crystal structure of 2-(2-bromophenyl)-5-ethyl-1,3-dioxane-5-carboxylic acid, C13H15BrO4
  73. Crystal structure of 4-(4-((3-bromophenyl)amino)-6-(tert-butyl)-3-(2-hydroxypropan-2-yl)cinnolin-8-yl)-2-methylbut-3-yn-2-ol, C26H30BrN3O2
  74. Crystal structure poly-(μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazolyl-κ2NN1:N2N)-(μ3-2,2′-(1,2-phenylene)diacetato-κ5-O1,O2:O2:O3,O4)cadmium(II), C22H19CdN5O4
  75. Crystal structure of bis(1-ethyl-6-fluoro-4-oxido-7-(piperazin-1-ium-1-yl)-1,8-naphthyridin-1-ium-3-carboxylate-κ2O,O′)copper(II) benzene-1, 4-dicarboxylate dihydrate, C38H42F2CuN8O12
  76. Redetermination of the crystal structure of potassium lithium molybdate monohydrate, KLiMoO4·H2O
  77. Crystal structure of [tris(2-benzimidazolylmethyl)amine-κ3N](isonicotinate-κO) cobalt(II) [tris(2-benzimidazolylmethyl)amine-κ3N](isonicotinic acid-κO) cobalt(II) triperchlorate, C60H51N16O16Cl3Co2
  78. The crystal structure of tris(μ2-1,3-bis(4,4,4-trifluoro-3-oxido-1-(oxo)but-2-en-1-yl)phenyl-κ4O,O′:O′′,O′′′)-bis(1,2-dimethoxyethane-κ2O,O′)dicerium(III), C50H38F18O16Ce2
  79. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-ol, C10H19NO
  80. Crystal structure of 2,4-dibenzoyl-N,N-dimethylbenzenamine, C22H19NO2
  81. The crystal structure of 2-(4-methoxyphenyl)-6,8-diphenyl-4-(phenylamino)quinazoline — acetonitrile (1/1), C35H28N4O
Downloaded on 21.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0038/html?lang=en
Scroll to top button